Comprehensive, guideline-driven management of bipolar disorder. Your psychiatrist provides expert mood stabilisation with mood-stabilising medication and atypical appropriate medication, guided by NICE CG185 and BAP recommendations, combined with psychoeducation and structured therapy.
40M+People affected globallyWHO, 2023
6-10 yrsAverage delay to correct diagnosisHirschfeld et al., JCP
25-50%Lifetime suicide attempt rateAPA Practice Guidelines
70%Response rate with mood-stabilising medication prophylaxisBAP Guidelines
Understanding Bipolar Disorder
Bipolar disorder is a chronic mood disorder characterised by recurrent episodes of mania (or hypomania) and depression. These mood episodes represent significant departures from a person's usual functioning and can profoundly affect relationships, work, and daily life. Bipolar disorder is one of the leading causes of disability worldwide among young adults.
NICE CG185 emphasises the importance of accurate diagnosis, noting that bipolar disorder is frequently misdiagnosed as unipolar depression. The average delay from symptom onset to correct diagnosis is 6-10 years, during which inappropriate medication monotherapy may worsen the course of illness.
NICE CG185 — Bipolar disorder: assessment and management
There are several subtypes: Bipolar I (characterised by full manic episodes), Bipolar II (characterised by hypomanic episodes and major depressive episodes), and Cyclothymic Disorder (chronic fluctuating mood disturbance). Accurate subtyping is essential for appropriate treatment planning.
Signs and Symptoms
Manic / Hypomanic Episodes
Elevated, expansive, or irritable mood lasting days to weeks
Decreased need for sleep without feeling tired
Racing thoughts and pressured, rapid speech
Grandiosity or inflated self-esteem
Increased goal-directed activity or psychomotor agitation
Impulsive, risky behaviour: overspending, reckless driving, sexual indiscretions
Depressive Episodes
Persistent sadness, hopelessness, or emptiness
Loss of interest or pleasure in nearly all activities
Significant changes in appetite and sleep patterns
Fatigue, psychomotor slowing, or difficulty concentrating
Feelings of worthlessness or excessive guilt
Recurrent thoughts of death or suicidal ideation
Our Treatment Approach
Both NICE CG185 and BAP guidelines recommend mood-stabilising medication as the first-line long-term treatment for bipolar disorder. It is the only mood stabiliser with robust evidence for reducing suicide risk. mood-stabilising medication, atypical appropriate medication (appropriate medication, appropriate medication), and mood-stabilising medication are important alternatives depending on the clinical presentation.
NICE CG185 & BAP Guidelines for Bipolar Disorder
1
Diagnostic Assessment
Thorough clinical evaluation using structured diagnostic tools, mood charting, detailed history of mood episodes, family history, substance use screening, and medical investigations to rule out organic causes.
2
Mood Stabilisation
mood-stabilising medication as first-line treatment per NICE and BAP guidelines, with regular therapeutic drug monitoring. mood-stabilising medication, appropriate medication, or appropriate medication as alternatives based on clinical profile, tolerability, and patient preference.
3
Acute Episode Management
Tailored pharmacological interventions for acute manic episodes (appropriate medication, mood-stabilising medication augmentation) and depressive episodes (appropriate medication, mood-stabilising medication, carefully managed combination therapy), with close monitoring.
4
Psychoeducation
Structured psychoeducation for patients and families about the nature of bipolar disorder, the importance of medication adherence, early warning sign identification, and lifestyle regularity to prevent relapse.
5
IPSRT & Long-Term Support
Interpersonal and Social Rhythm Therapy (IPSRT) to stabilise daily routines and sleep-wake cycles, combined with ongoing mood monitoring, relapse prevention planning, and family support.
Frequently Asked Questions
The average diagnostic delay of 6-10 years occurs because patients typically seek help during depressive episodes rather than manic ones. Hypomanic episodes may feel productive and go unreported. Without a detailed history of elevated mood states, the condition is often misdiagnosed as unipolar depression.
mood-stabilising medication has the strongest evidence base for long-term mood stabilisation in bipolar disorder, with over 60 years of clinical data. NICE CG185 and BAP guidelines both recommend it as first-line because it reduces both manic and depressive relapses and is the only mood stabiliser proven to reduce suicide risk.
Bipolar disorder is a chronic condition, and guidelines generally recommend long-term maintenance treatment. The decision about treatment duration is individualised, but discontinuing mood stabilisers carries a high risk of relapse. NICE CG185 recommends discussing this carefully with your psychiatrist.
Yes. Appropriate medication monotherapy in bipolar disorder can trigger manic episodes, accelerate mood cycling, and worsen the overall course of illness. This is why NICE CG185 recommends against using appropriate medication alone in bipolar disorder; they should only be used alongside mood stabilisers when necessary.
Sleep disruption is both a symptom and a trigger for mood episodes. Reduced sleep can precipitate mania, while hypersomnia is common during depression. Maintaining regular sleep-wake cycles is a cornerstone of relapse prevention, which is why IPSRT focuses heavily on circadian rhythm stabilisation.
Expert Bipolar Disorder Care
Accurate diagnosis and guideline-based treatment can transform the course of bipolar disorder. Take the first step toward stability and well-being.